Novo Nordisk: experimental growth hormone shows potential
(CercleFinance.com) - New phase 2 data for Novo Nordisk's somapacitan has demonstrated its potential as an efficacious once-weekly treatment for childhood growth hormone deficiency, the Danish drugmaker said on Friday.
In a trial comparing three somapacitan doses to Norditropin - another growth hormone that belongs to Novo - annualised height velocity did not differ significantly, the company said.
Also, somapacitan was well tolerated at all doses investigated, it added.
Somapacitan is a long-acting analogue of human growth hormone which is under investigation as a potential treatment for growth hormone deficiency.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
In a trial comparing three somapacitan doses to Norditropin - another growth hormone that belongs to Novo - annualised height velocity did not differ significantly, the company said.
Also, somapacitan was well tolerated at all doses investigated, it added.
Somapacitan is a long-acting analogue of human growth hormone which is under investigation as a potential treatment for growth hormone deficiency.
Copyright (c) 2018 CercleFinance.com. All rights reserved.